This trial is active not recruiting!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Epidermal Growth Factor Receptor or Non-Small Cell Lung Cancer
and you are
over 18
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

Patient with Non-Small Cell Lung Cancer (NSCLC) that might have a genetic change (mutation) in the Epidermal Growth Factor Receptor (EGFR) are invited to take part in this study. This research study is evaluating a new blood test that is capable of detecting an EGFR mutation in cancer without a biopsy.

Provided treatments

  • Drug: Erlotinib
Tris trial is registered with FDA with number: NCT02770014. The sponsor of the trial is Dana-Farber Cancer Institute and it is looking for 43 volunteers for the current phase.
Official trial title:
Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer